Drug intelligence / Profile preview

mipetresgene autoleucel

Development stage
Phase 2
Lead developer
Takara Bio
Modality
TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration
Intravenous
01

Overview

Mipetresgene autoleucel (TBI-1301) is an autologous T-cell receptor (TCR) gene therapy developed by Takara Bio Inc. for the treatment of NY-ESO-1-positive synovial sarcoma. The therapy consists of patient-derived T lymphocytes genetically modified using a retroviral vector (siTCR vector) to express an affinity-enhanced TCR specific for the NY-ESO-1 cancer-testis antigen, restricted to HLA-A*02:01 or HLA-A*02:06. To improve efficacy and safety, the vector also includes siRNA constructs designed to downregulate the expression of endogenous TCRs, thereby reducing TCR mispairing and enhancing the surface expression of the therapeutic TCR. It is currently in Phase 3 development in Japan, where it has received Sakigake and orphan drug designations.

Brand names
mipetresgene autoleucel
Other names
mipetresgene autoleucelTBI-1301TBI1301TBI 1301Mip-cel
02

Targets

HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)

Beyond the preview

Go deeper on mipetresgene autoleucel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mipetresgene autoleucel.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call